Protecting Our Future: Gavi’s Investment Opportunity 2026-2030

Protecting Our Future

Gavi’s Investment Opportunity 
2026-2030

Learn more

#ForOurFuture

The Vaccine Alliance plans to accelerate its impact between 2026-2030, leveraging the latest innovations in vaccines and vaccine delivery to protect 500 million children and saving over 8 million lives

Gavi's Investment Opportunity 2026–2030

• Download: English | French

• Executive summaries: 
  Arabic | Chinese | German | Italian | Japanese | Portuguese | Spanish 

• Everything you need to know about Gavi’s Investment Opportunity

• Gavi's Investment Opportunity by numbers

• Technical Appendix | Impact estimates FAQs

• Communications toolkit: English | French

Voices of support

The launch of Gavi's Investment Opportunity 2026-2030 brought together leaders from government, partner organisations, civil society and business, to accelerate sustainable immunisation and innovation for equitable health in Paris on 20 June 2024.

Hear what they said

The Global Forum for Vaccine Sovereignty and Innovation

Gavi, the Vaccine Alliance, the Government of France and the African Union – together with Team Europe partners – hosted The Global Forum for Vaccine Sovereignty and Innovation. The event was co-hosted on 20 June 2024 in Paris by the President of the French Republic, H.E. Mr. Emmanuel Macron, and the President of the Islamic Republic of Mauritania and Chair of the African Union, H.E. Mr. Mohamed Ould Cheikh Ghazouani.

The Forum launched Gavi’s 2026–2030 Investment Opportunity (IO) to support its next replenishment – which will raise funds for immunisation in lower-income countries for Gavi’s sixth strategic period, from 2026 through 2030 (Gavi 6.0). The Forum also launched the African Vaccine Manufacturing Accelerator (AVMA), an innovative financial mechanism, designed by Gavi in close collaboration with Africa Centres for Disease Control and Prevention (Africa CDC), to help vaccine manufacturers in Africa to scale up production and foster regional diversification of vaccine manufacturing.

AVMA will make a strong contribution to the African Union’s Partnerships for African Vaccine Manufacturing (PAVM) ambition to manufacture at least 60% of the total vaccine doses required on the continent by 2040, as well as the global effort to strengthen African health sovereignty at all times, including for pandemic preparedness and response.

Watch the full event

Protecting more children, against more diseases, faster than ever before: Gavi, the Vaccine Alliance unveils plans for next 5-year period

NEWS RELEASE | 21 June 2024

The Forum also saw the launch of the African Vaccine Manufacturing Accelerator (AVMA), an innovative financing mechanism which aims to foster regional vaccine production and vaccine sovereignty on the African continent, with twelve sovereign and philanthropic donors committing to invest approximately US$ 1.2 billion.